Literature DB >> 11043607

Distribution of [14C]suramin in tissues of male rats following a single intravenous dose.

W P McNally1, P D DeHart, C Lathia, L R Whitfield.   

Abstract

PURPOSE: Suramin has been shown to have efficacy in treatment of prostate cancer. In the present study we evaluated distribution of [14C]suramin in tissues over time following a single intravenous dose.
METHODS: Male rats were given a single IV dose of 300 mg/kg [14C]suramin and sacrificed at 1 or 6 hours, or at 1, 7, 14, 28, 56, or 84 days postdose. Radioactivity remaining in tissues was measured by quantitative whole body autoradiography.
RESULTS: At one hour highest tissue activity was found in blood vessel walls and caecum, followed by lung, blood, skin, preputial, thyroid, brown fat, heart, kidney, lymph nodes, liver, salivary, adrenal, Harder's and lacrimal glands, prostate, and spleen. Considerable activity was present in membranes surrounding muscle groups, bone and other organs. Relatively low activity was found in brain tissue although persistent concentration was evident in choroid plexus. High levels were present in bladder and caecum contents. Activity declined in blood but continued to increase in many tissues at later time points. Kidney reached maximum levels at 7 days postdose and retained concentration considerably higher than other tissues over the course of the study. Concentrations in tissues were persistent and considerable activity remained at 84 days postdose. Terminal elimination half life in tissues was prolonged, approximately 39 days in blood and 91 and 102 days in kidney and spleen, respectively. Uptake in prostate was highest in membranous structures separating secretory lobules.
CONCLUSION: Suramin is widely distributed to tissues and appears to have particular affinity for boundary membranes surrounding organs and other structural tissue elements, possibly due to uptake by glycosaminoglycans. Antitumor activity may be related to inhibition of growth factors associated with these elements.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11043607     DOI: 10.1016/s0024-3205(00)00767-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.

Authors:  Danny Chen; Sae Heum Song; M Guillaume Wientjes; Teng Kuang Yeh; Liang Zhao; Miguel Villalona-Calero; Gregory A Otterson; Rhonda Jensen; Michael Grever; Anthony J Murgo; Jessie L-S Au
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

2.  Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.

Authors:  Leijun Hu; M Guillaume Wientjes; Jing Li; Jessie L-S Au
Journal:  AAPS J       Date:  2010-07-13       Impact factor: 4.009

3.  Suramin inhibits renal fibrosis in chronic kidney disease.

Authors:  Na Liu; Evelyn Tolbert; Maoyin Pang; Murugavel Ponnusamy; Haidong Yan; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 10.121

4.  Suramin as a chemosensitizer: oral pharmacokinetics in rats.

Authors:  Adam Ogden; M Guillaume Wientjes; Jessie L S Au
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

5.  The effects of Suramin on Ca2+ activated force and sarcoplasmic reticulum Ca2+ release in skinned fast-twitch skeletal muscle fibers of the rat.

Authors:  Dane W Williams; Dimitrie George Stephenson; Giuseppe S Posterino
Journal:  Physiol Rep       Date:  2017-07

6.  Effect of Suramin on Renal Proximal Tubular Cells Damage Induced by Cisplatin in Rats (Histological and Immunohistochemical Study).

Authors:  Eman Ali El-Kordy
Journal:  J Microsc Ultrastruct       Date:  2019-11-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.